AI could spot liver cancer types and predict survival without needle biopsy

NCT ID NCT07658586

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentiate between two common liver cancer types—hepatocellular carcinoma and intrahepatic cholangiocarcinoma—without needing a biopsy. It will also estimate how long patients might live without the cancer returning after tumor removal. The research involves at least 600 patients and uses past medical data to train and test the AI model.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Artificial intelligence model
What this could lead to
If successful, this AI system could help doctors diagnose liver cancer subtypes more accurately without invasive biopsies and better predict patient outcomes after surgery.
What could go wrong
This is a retrospective study using existing data, not a prospective trial. The AI model may not perform as well in real-world settings or on diverse patient populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension hepatocellular carcinoma intrahepatic cholangiocarcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Guangxi Medical University First Affiliated Hospital

    Nanning, Guangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.